Nab-paclitaxel trials for PDAC - Pancreatic Ductal Adenocarcinoma

All Nab-paclitaxel trials · All PDAC - Pancreatic Ductal Adenocarcinoma trials

Phase breakdown

Recruiting trials studying Nab-paclitaxel for PDAC - Pancreatic Ductal Adenocarcinoma

• A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
  NCT07049055 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations

Common questions

How many trials study Nab-paclitaxel for PDAC - Pancreatic Ductal Adenocarcinoma?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.